Your Body Or Your Face - Your Thighs Or Your Eyes? Which Would You Choose To Improve?
The contest begins Monday, November 12 and ends Sunday, November 30, 2012. One lucky grand prize winner will be selected at the end of the contest to win a series of four customized VelaShape® treatments with a premier Syneron physician. The winner will also be awarded a trip to New York City to meet Rickie Freeman of Teri Jon® in her glam showroom where she will receive a customized Little Vela Dress fitted just for her. Finally, the contest will include a makeover – hair and makeup – done by a celebrity stylist and will conclude with a professional photo shoot. The total prize package is valued at $5,000. Ten lucky runners-up will also be chosen at random to win a $100 gift card to shop at www.terijon.com. All winners will be announced Monday, December 1.
About VelaShape®It's estimated that anywhere from 85 percent to 98 percent of women over the age of 16 have cellulite. A recent survey of American women 25 and up identified their tummy bulge (70 percent) as their #1 concern followed by muffin top (55 percent) and cellulite (45 percent) 4. VelaShape is the non-surgical alternative that's clinically proven to temporarily reduce the appearance of cellulite while smoothing and shaping the areas that diet and exercise can't quite fix. With over 500,000,000 million media impressions, over 10,000 procedures performed every day and over 40 published clinical studies, VelaShape® remains the trusted technology for cellulite and non-surgical body shaping by physicians, beauty experts and millions of patients worldwide.
About Syneron Medical Ltd.Syneron Medical Ltd. – a company devoted to real technology, real science and real results – is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. The Company's aspiration and commitment to innovation expands Syneron's offering beyond medical device into the largest in-demand applications in beauty - skin lightening. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at www.syneron.com.SAFE HARBOR FOR FORWARD-LOOKING STATEMENTSAny statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts